Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

The "Chronic Spontaneous Urticaria Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.65% to $605.61 Friday, on what proved to be an all-around favorable ...

Sanofi is racing to raise the flag on meningitis awareness—literally. The Paris-based pharma is fittingly symbolizing the “race against time” that is the fight against rapidly progressing ...

Sanofi becomes a pure play pharma after 50% stake sale in Opella Sanofi (SNY) completed the sale of a 50% stake in Opella, turning its focus towards biopharma exclusively. The transaction provided ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...